Pål Andrè Holme is Professor of Haematology and Senior Haematologist at the Department of Haematology and Institute of Clinical Medicine, Oslo University and Oslo University Hospital, Rikshospitalet, Norway. He graduated from the Medical School at the University of Oslo in 1993 and was a research fellow at the Institute for Internal Medicine, University of Oslo, where he earned a PhD in 1996 after studies on platelet activation and platelet-derived-microparticle formation. He is a specialist in internal medicine and haematology. Prof. Holme has been responsible for the treatment of adult patients with haemophilia and bleeding related disorders in Norway since 2006. He leads a research group at Institute of Clinical Medicine and participates in several clinical research groups and has for a long time been an active investigator in studies on bleeding related disorders and platelets, and has authored many papers published in peer-reviewed journals and textbook chapters on these subjects.
Bayer, Octopharma, Pfizer, Sobi and Takeda.
Will the expert panellists change the way you think about managing haemophilia?